Absci (ABSI) Return on Capital Employed (2021 - 2026)
Absci (ABSI) posted Return on Capital Employed of 66.39% for Q1 2026, down 14.71% sequentially from 57.88% in Q4 2025, and down 860.0% YoY from 8.74% in Q1 2025.
Absci (ABSI) Return on Capital Employed (2021 - 2026) Analysis & Trends
Absci has reported Return on Capital Employed for 6 years, with the latest figure at 66.39% in Q1 2026.
- Quarterly Return on Capital Employed fell 860.0% year-over-year to 66.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66.39% (down 860.0% YoY) and the FY2025 annual result came in at 62.6%, down 431.0% from the prior year.
- Return on Capital Employed declined to 66.39% in Q1 2026 per ABSI's latest filing, from 57.88% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 25.18% in Q1 2022 and troughed at 66.39% in Q1 2026.
- A 5-year average of 48.18% and a median of 51.49% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 2297 bps in 2023, then jumped 572 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 35.59% in 2022, then slumped by 65 bps to 58.56% in 2023, then increased by 5 bps to 55.62% in 2024, then slipped by 4 bps to 57.88% in 2025, then fell by 15 bps to 66.39% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 66.39%, 57.88%, and 60.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | -59.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.34% |
| Mar 31, 2026 | -66.39% |
| Dec 31, 2025 | -57.88% |
| Sep 30, 2025 | -60.21% |
| Jun 30, 2025 | -62.05% |
| Mar 31, 2025 | -57.79% |
| Dec 31, 2024 | -55.62% |
| Sep 30, 2024 | -47.49% |
| Jun 30, 2024 | -40.99% |
| Mar 31, 2024 | -51.87% |
| Dec 31, 2023 | -58.56% |
| Sep 30, 2023 | -51.49% |
| Jun 30, 2023 | -46.71% |
| Mar 31, 2023 | -36.43% |
| Dec 31, 2022 | -35.59% |
| Sep 30, 2022 | -34.67% |
| Jun 30, 2022 | -30.09% |
| Mar 31, 2022 | -25.18% |
| Dec 31, 2021 | -18.63% |
| Sep 30, 2021 | -16.61% |